Drugs / JY09
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04354090 | Apr → Dec 2018 | type 2 diabetes mellitus | Beijing Dongfang Biotech Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02971722 | Dec 2016 → May 2017 | — | Beijing Dongfang Biotech Co., Ltd. | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06257966 | Jul 2024 → Oct 2026 expected | type 2 diabetes mellitus | Beijing Dongfang Biotech Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JY09 | “Exendin-4Fc fusion protein (JY09) injection” NCT06257966 ↗ |
| Known as | Exendin-4Fc fusion protein | “Exendin-4Fc fusion protein (JY09) injection” NCT06257966 ↗ |
| Action | Activate | “recombinant glucagon-like peptide-1 (GLP-1) receptor agonist” NCT02971722 ↗ |
| Modality | Protein / enzyme biologic | “JY09，is a recombinant glucagon-like peptide-1 (GLP-1) receptor agonist,constructed with Exendin-4 and human Immunoglobulin G2 (IgG2) Fc fragment.” NCT02971722 ↗ |
| Route | Subcutaneous | “0.3mg JY09 administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods” NCT02971722 ↗ |